Name Shirin Muhsen, MD, EMBA, CPHQ
Title Chief Quality Officer
Primary Specialty General Surgery
Languages: Arabic & English
Contact Details
Email [email protected]
Phone +974 4400 4400

Social Media

Scope of Practice

  • Breast Surgery
  • Colorectal surgery
  • Thyroid Surgery
  • Inguinal and Abdominal Hernia Repairs
  • Gallbladder surgery
  • Appendectomy
  • Acute Care Surgery

Highlights

Academic Achievements:

0 +
Publications
0 +
Abstracts
0 +
Awards
0 +
Book

Experience & Education

  • Consultant General Surgeon -Beirut, Lebanon
  • Executive in Masters Business Administration -American University of Beirut, Lebanon
  • Colorectal Surgical Oncology Fellow -Memorial Sloan Kettering Cancer Center, New York
  • Breast Surgical Oncology Fellow -Memorial Sloan Kettering Cancer Center, New York
  • General Surgery Residency -American University of Beirut Medical Center, Lebanon
  • Research Fellow, Breast Department -Memorial Sloan Kettering Cancer Center, New York
  • Doctor of Medicine -American University of Beirut, Lebanon

Certifications & Memberships

  • Certified Professional in Healthcare Quality Examination (CPHQ)
  • Member of the American College of Surgeons (ACS)
  • Member of the American Society of Breast Surgeons (ASBrS)
  • Candidate Member of the American Society of Colon and Rectal Surgeons (ASCRS)
  • Member of the European Society of Surgical Oncology (ESSO)
  • Member of the American College of Health Care Executives (ACHE)
  • Member of the Lebanese Society for Quality and Safety in Health Care (LSQSH)

Publications

Most Recent

  • Crown A, Muhsen S, Zabor EC, Sevilimedu V, Kelvin J, Goldfarb S, Gemignani ML. Does Use of Neoadjuvant Chemotherapy Affect Decision to Pursue Fertility Preservation Options in Young Women with Invasive Breast Cancer? (Accepted for Publication in Annals of Surgical Oncology)
  • Valero MG, Moo TA, Muhsen S, Zabor EC, Stempel M, Pusic A, Gemignani ML, Morrow M, Sacchini VS. Use of Bilateral Prophylactic Nipple-Sparing Mastectomy in Patients with High Risk of Breast Cancer. (Accepted for Publication in Br J Surg)
  • Valero MG, Muhsen S, Moo TA, Zabor EC, Stempel M, Pusic A, Gemignani ML, Morrow M, Sacchini VS. Increase in Utilization of Nipple Sparing Mastectomy for Breast Cancer: Indications, Complications, and Oncologic Outcomes. Ann Surg Oncol. 2020 Feb;27(2):344-351
  • Miller ME, Muhsen S, Zabr EC, Flynn J, Olcese C, Giri D, Van Zee KJ, Pilewskie. Risk of Contralateral Breast Cancer in Women with Ductal Carcinoma In Situ Associated with Synchronous Ipsilateral Lobular Carcinoma in Situ. Ann Surg Oncol. 2019 Dec;26(13):4317-4325
  • Baker JL, Muhsen S, Zabor EC, Stempel M, Gemignani ML. Does Lymph Node Status Prior to Neoadjuvant Chemotherapy Influence the Number of Sentinel Nodes Removed? Ann Surg Oncol. 2019 Feb;26(2):336-342
See more publications
  1. Muhsen S, Moo TA, Patil S. Stempel M, Powell S, Morrow M, El-Tamer M. Most breast cancer patients with T1-2 tumors and 1-3 positive lymph nodes do not need post mastectomy radiotherapy. Ann Surg Oncol. 2018 Jul;25(7):1912-1920.
  2. Muhsen S, Barrio AV, Miller M, Olcese C, Patil S, Morrow M, Van Zee KJ. Outcomes for Women with Minimal-Volume Ductal Carcinoma In Situ Completely Excised at Core Biopsy. Ann Surg Oncol 2017;24(13):3888-95.
  3. Miller ME, Muhsen S, Olcese C, Patil S, Morrow M, Van Zee KJ. Contralateral Breast Cancer Risk in Women with Ductal Carcinoma In Situ: Is it High Enough to Justify Bilateral Mastectomy? Ann Surg Oncol. 2017;24(10):2889-2897.
  4. De Brot M, Koslow Mautner S, Muhsen S, Andrade VP, Mamtani A, Murray M, Giri D, Sakr RA, Brogi E, King TA. Pleomorphic lobular carcinoma in situ of the breast: a single institution experience with clinical follow-up and centralized pathology review. Breast Cancer Res Treat 2017;165(2):411-20.King TA, Pilewskie M, Muhsen S, Patil S, Mautner SK, Park A, Oskar S, Guerini-Rocco

  5. E, Boafo C, Gooch JC, De Brot M, Reis-Filho JS, Morrogh M, Andrade VP, Sakr RA,

    Morrow M. Lobular Carcinoma in Situ: A 29-Year Longitudinal Experience Evaluating Clinicopathologic Features and Breast Cancer Risk. J Clin Oncol 2015;33(33):3945-52.

  6. Andrade VP, Morrogh M, Qin LX, Olvera N, Giri D, Muhsen S, Sakr RA, Schizas M, Ng CK, Arroyo CD, Brogi E, Viale A, Morrow M, Reis-Filho JS, King TA. Gene expression profiling of lobular carcinoma in situ reveals candidate precursor genes for invasion. Mol Oncol 2015;9(4):772-82.
  7. King TA, Muhsen S, Patil S, Koslow S, Oskar S, Park A, Morrogh M, Sakr RA, Morrow M. Is there a role for routine screening MRI in women with LCIS? Breast Cancer Res Treat 2013;142(2):445-53.
  8. Hussein M, Issa G, Muhsen S, Haydar A. Superior mesenteric arteriovenous fistula embolisation complicated by bowel ischaemia. BMJ Case Rep 2013;2013.
  9. King TA, Sakr RA, Muhsen S, Andrade VP, Giri D, Van Zee KJ, Morrow M. Is there a low-grade precursor pathway in breast cancer? Ann Surg Oncol 2012;19(4):1115-21.